Can a Telehealth Brand Advertise Retatrutide?

What this means for you

• Retatrutide is an investigational drug still in clinical trials. FDA says it cannot be used in compounding and is not a component of any FDA-approved drug.
• FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers.
• For LegitScript-certified businesses, offering, promoting or advertising retatrutide is a violation, and so is content that encourages its use, whether or not the business sells it.
• Meta needs active LegitScript certification for prescription drug ads and TikTok needs proof of FDA approval, while Google's unapproved substances rules and Microsoft's ban on experimental treatments close the other routes.
• Waitlists, research-use sales and education pages that end in a call to action are not workarounds.

MedScale Health, a paid ads agency for US telehealth brands and clinics on Meta, Google, Microsoft and TikTok, gets asked about retatrutide by GLP-1 brands. This page sets out FDA's position, LegitScript's September 22, 2026 guidance, what each ad platform allows, and why an education funnel does not change the answer. This page is marketing guidance, not medical or legal advice. Platform policies and FDA positions change, so check the sources listed at the end before acting on a specific rule.

FDA's position

As of October 2026, FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, is direct: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition." The same section says FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers, and warned ingredient distributors and outsourcing facilities that sold or repackaged it.

FDA has also warned companies that sold unapproved drugs containing retatrutide and other GLP-1s labeled "for research purposes" or "not for human consumption", which FDA says were sold directly to consumers for human use with dosing instructions. Our answer on research peptides versus prescribed peptides covers why that label changes nothing.

Why it can't be compounded

LegitScript's post explains the mechanics. A 503A pharmacy generally needs a substance to be on the 503A Bulk Drug Substances List, the subject of a USP or National Formulary monograph, or a component of an FDA-approved drug. 503B outsourcing facilities can only compound substances on Category 1 of the 503B Bulks List. LegitScript says retatrutide and cagrilintide remain investigational drugs still in clinical trials, haven't gone through FDA's compounding advisory committee review at all, and meet none of these thresholds.

That puts retatrutide behind peptides such as BPC-157, which FDA's Pharmacy Compounding Advisory Committee has reviewed. Even there, LegitScript notes that an advisory recommendation doesn't authorize compounding or change the law; only a final rule changes a substance's status.

LegitScript: offering, promoting and advertising all count

LegitScript's September 22, 2026 post, "The Peptide Boom: Why So Many Popular Products Are Still Off-Limits", says violations "aren't limited to actually dispensing or prescribing an impermissible peptide. They also include offering the product, promoting it, or advertising it." Partnering with a separate entity that dispenses or prescribes on the business's behalf "doesn't provide a workaround either", and businesses found in violation "will be subject to enforcement action."

That certificate is the key to a telehealth brand's prescription drug advertising: Meta requires active LegitScript certification, and Google allows US telemedicine providers accredited by LegitScript. A retatrutide ad puts the certificate behind every other ad at risk.